Pfizer Stock Outlook: The High-Stakes Obesity BetPfizer (NYSE: PFE) has underperformed the broader healthcare rally, sliding 5% since October. While competitors like Eli Lilly soar, Pfizer struggles to replace waning COVID-19 vaccine revenue. However, management is executing an aggressive pivot. The company recently committed over $12 billion to e
Key facts today
Pfizer Inc. will host a call with analysts on February 3, 2026, at 10:00 a.m. EST to discuss its Q4 and Full Year 2025 performance report, released that day.
In 2026, Medicare enrollees will see nearly 50% lower out-of-pocket costs for some Pfizer drugs due to price negotiations from the Inflation Reduction Act of 2022.
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
1.72 USD
8.02 B USD
63.63 B USD
5.68 B
About Pfizer, Inc.
Sector
Industry
CEO
Albert Bourla
Website
Headquarters
New York
Founded
1849
Identifiers
3
ISINUS7170811035
Pfizer Inc is a research-based global biopharmaceutical company. It engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.
Related stocks
PFEPfizer (PFE) is moving in a clear uptrend, forming higher lows along the rising trendline.
A good entry level is around $26, where price may retest the trendline before moving higher.
The main target is $30, which represents strong horizontal resistance.
The stop loss at $23 protects the trade, as a
$PFE - Pfizer still near 2020 Covid LowsPfizer is still trading below its 2020 Covid lows. Pfizer continues to advance its drug development pipeline, including oncology candidates and supplemental indications, and recent FDA activity demonstrates progress in cancer therapies and other areas. The company is focused on delivering multiple n
Pfizer (PFE)Pfizer (PFE) – Technical Structure Suggests a Broad Rounded Bottom Formation
Pfizer continues to develop a large, multi-month rounded bottom structure on the daily chart. The price action since late 2023 shows three distinct and symmetrical troughs around the 25–26 zone, forming a wide Rounded Trip
Pfizer (PFE) – Hedged Covered Call Income CampaignAfter Pfizer’s return to price levels closer to its pre-COVID range, I personally believe the stock is undervalued relative to its current earnings profile and long-term potential. This view is also influenced by Pfizer’s recent acquisition of Metsera, which brings a pipeline of obesity and cardiome
Pfizer stock exploded as expected from weekly demandPfizer just did it again!
After weeks of sleeping inside that weekly demand imbalance, the pharmaceutical giant exploded — exactly as expected from our supply and demand forecast. Price has already rallied more than 7%, proving once again how powerful these imbalances can be when you learn to read
Dividend Dose & Breakout BouncePfizer has developed an interesting technical setup: the stock is currently holding above a gap around $23.50, and a breakout above $26.50 could pave the way toward the $27.69 resistance level. With a stop‑loss placed at $23.58, this trade presents a strong risk‑to‑reward ratio.
From a fundamental
PFE QuantSignals V3 Earnings 2025-11-03PFE QuantSignals V3 Earnings 2025-11-03
PFE Earnings Signal | 2025-11-03
• Direction: BUY CALLS | Confidence: 72%
• Entry Plan: Open | Expiry 2025-11-07
• Strike Focus: $24.50
• Entry Range: $0.47
• Target 1: $0.94
• Stop Loss: $0.28
• Implied Move: $1.12 (4.6%)
• 24h Move: +0.06%
• Flow Intel: Bull
Pfizer “shows its claws”: between litigation&boost searchPfizer “shows its claws”: between litigation and the search for a new boost
By Ion Jauregui – Analyst at ActivTrades
Pfizer (NYSE: PFE) is back in Wall Street’s spotlight after filing a lawsuit against Metsera (NASDAQ: MTSR) and Novo Nordisk (CPH: NOVOb), accusing them of breaching a merger agr
See all ideas
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
P
PFE5588844
Pfizer Investment Enterprises Pte. Ltd. 5.34% 19-MAY-2063Yield to maturity
5.80%
Maturity date
May 19, 2063
P
PFE5588843
Pfizer Investment Enterprises Pte. Ltd. 5.3% 19-MAY-2053Yield to maturity
5.64%
Maturity date
May 19, 2053
P
PFE5588591
Pfizer Investment Enterprises Pte. Ltd. 5.11% 19-MAY-2043Yield to maturity
5.42%
Maturity date
May 19, 2043
See all PFE bonds
Curated watchlists where PFE is featured.
Frequently Asked Questions
The current price of PFE is 25.05 USD — it has decreased by −1.92% in the past 24 hours. Watch Pfizer, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NYSE exchange Pfizer, Inc. stocks are traded under the ticker PFE.
PFE stock has fallen by −1.77% compared to the previous week, the month change is a −0.28% fall, over the last year Pfizer, Inc. has showed a −4.37% decrease.
We've gathered analysts' opinions on Pfizer, Inc. future price: according to them, PFE price has a max estimate of 36.16 USD and a min estimate of 23.00 USD. Watch PFE chart and read a more detailed Pfizer, Inc. stock forecast: see what analysts think of Pfizer, Inc. and suggest that you do with its stocks.
PFE stock is 0.98% volatile and has beta coefficient of 0.58. Track Pfizer, Inc. stock price on the chart and check out the list of the most volatile stocks — is Pfizer, Inc. there?
Today Pfizer, Inc. has the market capitalization of 142.37 B, it has decreased by −2.95% over the last week.
Yes, you can track Pfizer, Inc. financials in yearly and quarterly reports right on TradingView.
Pfizer, Inc. is going to release the next earnings report on Feb 3, 2026. Keep track of upcoming events with our Earnings Calendar.
PFE earnings for the last quarter are 0.87 USD per share, whereas the estimation was 0.63 USD resulting in a 37.52% surprise. The estimated earnings for the next quarter are 0.59 USD per share. See more details about Pfizer, Inc. earnings.
Pfizer, Inc. revenue for the last quarter amounts to 16.65 B USD, despite the estimated figure of 16.50 B USD. In the next quarter, revenue is expected to reach 17.04 B USD.
PFE net income for the last quarter is 3.54 B USD, while the quarter before that showed 2.88 B USD of net income which accounts for 22.74% change. Track more Pfizer, Inc. financial stats to get the full picture.
Yes, PFE dividends are paid quarterly. The last dividend per share was 0.43 USD. As of today, Dividend Yield (TTM)% is 6.87%. Tracking Pfizer, Inc. dividends might help you take more informed decisions.
Pfizer, Inc. dividend yield was 6.37% in 2024, and payout ratio reached 120.11%. The year before the numbers were 5.73% and 441.41% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Dec 18, 2025, the company has 81 K employees. See our rating of the largest employees — is Pfizer, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Pfizer, Inc. EBITDA is 26.15 B USD, and current EBITDA margin is 36.93%. See more stats in Pfizer, Inc. financial statements.
Like other stocks, PFE shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Pfizer, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Pfizer, Inc. technincal analysis shows the sell today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Pfizer, Inc. stock shows the sell signal. See more of Pfizer, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
















